First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2013-03-11 11:48:37Open Document File Size: 85,37 KBShare Result on FacebookCityOrlando / Barcelona / Boston / PPAR / /CompanyACS / THOMSON REUTERS / Proc Natl Acad Sci U S A / Genfit SA / /CountryUnited States / Spain / / /EventFDA Phase / /IndustryTermtherapy for obesity / food effect study / Treatment of Cardiometabolic Disorders / placebo / Diabetes Care / /MedicalConditionglucose intolerance / reached epidemic proportions / fatty liver disease / especially abdominal obesity / P.Z. The metabolic syndrome / abdominal obesity / liver dysfunction / fatty liver dysfunction / inflammatory markers / hepatic dysfunction / obesity / gastritis / moderate headache / diarrhea / mild gastroenteritis / Metabolic disorders / cardiovascular diseases / back pain / H. Fatty liver / hepatic fibrosis / multiple abnormalities / glucose disorders / insulin resistance / Cardiovascular disorders / hypertension / atherosclerotic cardiovascular disease / disease / atherosclerosis / chronic liver disease / non-alcoholic fatty liver disease / dyslipidemia / prediabetes / atherogenic dyslipidemia / diabetes / cardiovascular disease / inflammatory component / metabolic syndrome / obesity-associated metabolic disorders / diabetes mellitus / atrial fibrillation / inflammation / S.M. Atherogenic dyslipidemia / Cardiometabolic Disorders / fibrosis / /MedicalTreatmenthemodilution / /OrganizationDiabetes Assoc / GFT-505 administration / /PersonVan Gaal / Genfit / /PositionDISCLOSURES The author / /Producttriad / simvastatin / glucagon / fenofibrate / GFT505-209 / GFT505209-4 / GFT-505 / GFT505-210 / /TechnologyPHARMACOKINETICS / artificial intelligence / gene expression / condensation / CVD / /SocialTag |